These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30838391)

  • 1. Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa.
    Cojutti PG; Maximova N; Schillani G; Hope W; Pea F
    J Antimicrob Chemother; 2019 Jun; 74(6):1648-1655. PubMed ID: 30838391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG; Morandin E; Baraldo M; Pea F
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Landersdorfer CB; Hüttner SJ; Drusano GL; Kinzig M; Holzgrabe U; Stephan U; Sörgel F
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1275-82. PubMed ID: 20065059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.
    Pea F; Viale P; Damiani D; Pavan F; Cristini F; Fanin R; Furlanut M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3550-3. PubMed ID: 16048982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and
    Cojutti PG; Candoni A; Lazzarotto D; Filì C; Zannier M; Fanin R; Pea F
    Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32825109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
    Georges B; Conil JM; Ruiz S; Seguin T; Cougot P; Fourcade O; Houin G; Saivin S
    Br J Clin Pharmacol; 2012 Apr; 73(4):588-96. PubMed ID: 21988468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S; Pai MP; Lodise TP
    J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization.
    Cojutti PG; Gatti M; Rinaldi M; Tonetti T; Laici C; Mega C; Siniscalchi A; Giannella M; Viale P; Pea F
    Front Pharmacol; 2021; 12():781892. PubMed ID: 34955851
    [No Abstract]   [Full Text] [Related]  

  • 11. Superiority of ceftazidime off-label high-dose regimen in PK/PD target attainment during treatment of extensively drug-resistant Pseudomonas aeruginosa infections in cancer patients.
    Zavrelova A; Sima M; Malakova J; Rozsivalova P; Paterova P; Zak P; Visek B; Michalickova D; Slanar O; Radocha J
    Br J Clin Pharmacol; 2023 Apr; 89(4):1452-1461. PubMed ID: 36422512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
    Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
    Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia.
    Jaruratanasirikul S; Wongpoowarak W; Jullangkoon M; Samaeng M
    J Pharmacol Sci; 2015 Feb; 127(2):164-9. PubMed ID: 25727953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.
    Loo AS; Neely M; Anderson EJ; Ghossein C; McLaughlin MM; Scheetz MH
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5854-9. PubMed ID: 24018264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacodynamic optimization of ceftazidime against Pseudomonas aeruginosa: continuous infusion or intermittent administration?].
    Aguilar L; Giménez MJ; Martín JE; Prieto J
    Rev Esp Quimioter; 2005 Mar; 18(1):21-5. PubMed ID: 15915228
    [No Abstract]   [Full Text] [Related]  

  • 18. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
    J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.